Bleomycin in combination chemotherapy of metastatic wilms tumor: A late recurrent case, refractory to conventional therapy

Authors

  • Dr. Tomas Kisielius MD,

    Corresponding author
    1. Medical Oncology Section, Department of Medicine, and The Cancer Center, Northwestern University Medical School, Chicago
    • 645 North Michigan, Suite 1040, Chicago IL 60611
    Search for more papers by this author
  • Adrian Bianco MD,

    1. Medical Oncology Section, Department of Medicine, and The Cancer Center, Northwestern University Medical School, Chicago
    Search for more papers by this author
  • John M. Merrill MD,

    1. Medical Oncology Section, Department of Medicine, and The Cancer Center, Northwestern University Medical School, Chicago
    Search for more papers by this author
  • S. G. Taylor IV MD,

    1. Medical Oncology Section, Department of Medicine, and The Cancer Center, Northwestern University Medical School, Chicago
    Search for more papers by this author
  • William Dewys MD

    1. Medical Oncology Section, Department of Medicine, and The Cancer Center, Northwestern University Medical School, Chicago
    Search for more papers by this author

Abstract

A patient with a late recurrence (13 years) of Wilms tumor is presented. After relapse with conventional chemotherapy, an objective partial remission was obtained with bleomycin, vinblastine, cyclophosphamide, and cis-platinum. Stable disease was noted when bleomycin was withheld. Bleomycin in this combination appeared to effect a good response, and further studies of chemotherapy of Wilms tumor should include bleomycin in combination with other active agents.

Ancillary